Polypeptide having the ability to form connections of glucosyl units in alpha-1,3 on an acceptor

ABSTRACT

An isolated polypeptide having the ability to specifically form connections of glucosyl units in alpha 1,3 on an acceptor including at least one hydroxyl moiety. The polypeptide includes i) the pattern I of sequence SEQ ID NO: 1, ii) the pattern II of sequence SEQ ID NO: 2, iii) the pattern II of sequence SEQ ID NO: 3, iv) the pattern IV of sequence SEQ ID NO: 4 or derivates from one or several of said patterns. The polypeptide furthermore has the aspartic residue (D) in position 5 of the pattern II (SEQ ID NO: 2), the glutamic acid residue (E) at position 6 of the pattern III (SEQ ID NO: 3) and the aspartic acid residue (D) in position 6 of the pattern IV (SEQ ID NO: 4); and its uses.

The present international application claims priority of application FR 13/01402 filed on 17 Jun. 2013, which is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to an isolated polypeptide having the ability to form connections of glucosyl units in alpha 1,3 on an acceptor, a polynucleotide encoding said polypeptide, its use in a production process of acceptors connected to glucosyl units in alpha 1,3, said acceptors connected to glucosyl units in alpha 1,3 and the use thereof.

PRIOR ART

Glucosyltransferases are enzymes capable of catalysing the synthesis of glucose polymers from an inexpensive substrate, such as sucrose, alone or in the presence of an acceptor of glucosyl units comprising at least one hydroxyl moiety. Within these acceptor molecules, the glucosyl units are coupled by glycosidic linkages of variable nature (α-1,6, α-1,4, α-1,2 or α-1,3).

The transglucosylases (or glucan saccharases) belonging to the family 70 of glycoside hydrolases (database: Carbohydrate Active Enzymes database and CANTAREL et al, Nucleic Acids Res., Vol. 37, p: D233-238 2009) are enzymes naturally produced by lactic acid bacteria of the genera Leuconostoc, Lactobacillus, Streptococcus or Weissela. Starting from their substrate, in particular sucrose, a renewable and cheap substrate, these enzymes catalyse the synthesis of homopolymers of glucosyl units (glucans) generally of very high molecular weight and having various structures (α-1,6/α-1,4/α-1,2 and/or α-1,3) glycosidic bonds. Also, if hydroxylated molecules are added to the reaction medium on top of the donor of glucosyl units, these enzymes may also include these molecules at the detriment of the synthesis of polymer, resulting in a wide range of oligosaccharides and/or gluco-conjugates.

From the work described in JEANES et al. (1954), describing the purification and the characterisation of glucans produced by 96 strains of Leuconostoc sp., those produced by the strain Leuconostoc mesenteroides NRRL B-742 are known (also found in L mesenteroides ATCC 13146, and since reclassified in L. citreum NRRL B-742). In effect, it produces two types of glucans: the fraction S and the fraction L.

The first glucan is composed of 50% of α-1,6 bonds in its main chain and 50% in of connections in α-1,3 (fraction S). Successive studies of the latter glucan described in JEANES & SEYMOUR (Carbonate Research, vol. 74, p: 31-40), COTE & ROBYT (Carbohydrate Research, vol. 119, p: 141-156, 1983) and REMAUD et al (J. Carbohydrate Chemistry, vol. 11 (3), 1992) showed that the latter had an original comb-like structure. More specifically, each glucosyl unit of the straight chain in this structure was branched in α-1,3 by a single glucosyl unit.

The second glucan (fraction L) produced by the same strain was composed of 73% of α-1,6 bonds and 14% of α-1,4 bonds at branching points (SEYMOUR et al., Carbohydrate Research, vol. 74, p: 41-62, 1979).

These various studies have shown that the strain L. citreum NRRL B-742 has several coding genes for transglucosylases responsible for the synthesis of glucans; which have different specificities. In the presence of extracts of this strain, it was thus possible to produce gluco-oligosaccharides which proved to have strong prebiotic properties stimulating the growth of Bifidobacterium sp. and of Lactobacillus sp. eg (CHUNG & DAY, Journal of Industrial Microbiology & Biotechnology, vol. 29, p:196-199, 2002; CHUNG & DAY, Poultry Science, vol. 83, p:1302-1306, 2004; brevet U.S. Pat. No. 7,772,212).

Now, although this strain has been known for more than fifty years, the enzymes responsible for the synthesis of these glucans are still not known. It must indeed be understood that if some of these enzymes are extracellular; others, however, remain strongly associated with the cells, including the enzyme responsible for the glucans with a high content of α-1,3 bonds (REMAUD et al., 1992). This strong association to the bacterial cells ensures that its purification and detailed characterisation could not be performed.

In 2000, Kim et al. described the cloning in E. coli of a transglucosylase resulting from this strain, called DsrB-742. The characterisation of the gene in question showed that it had 95% similarity with that of the already characterised DSR-B in L citreum NRRL B-1299 and had a polymerisation activity of the glucosyl units in α-1,6, but no specific connection activity in α-1,3.

Finally, the identification and the biochemical characterisation of the enzyme responsible for the synthesis of comb-like glucans (S) compounds of 50% of connections in α-1,3 therefore had remained totally unsuccessful so far.

DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the primary structure of the reference protein α-1,3 BrS resulting from the strain L. citreum NRRL B-742.

FIG. 2 shows profiles of chromatographic analyses by HPAEC-PAD.

FIG. 3 shows an NMR profile.

FIG. 4 shows profiles of chromatographic analyses by HPAEC-PAD.

FIGS. 5 and 6 show the evolution of the rate of α-1,3 bonds depending on the sucrose/hydroxylated acceptor ratio for the whole enzyme and the truncated enzyme respectively.

FIGS. 7 and 8 show an NMR spectrum.

SUMMARY OF THE INVENTION

The inventors have now demonstrated that the synthesis of comb-like dextrans by the strain L. citreum NRRL B-742 was due to the action, not of one but of two separate transglucosylases: one responsible for the synthesis of a linear dextran, and the other responsible for connections in α-1,3 on these linear chains that act as acceptor molecules. The inventors have therefore identified a polypeptide having an enzymatic activity which had never been described before, responsible for specific connections of glucosyl units in α-1,3 on acceptor molecules, e.g. such as dextrans. Note further that the inventors were able to control the connection rate of these glycosyl units. Finally, the inventors were able to identify two orthologues of this protein sequences in two other strains of Leuconostoc.

So this is the first natural branching enzyme described for a transglucosylase which, by sequence analysis, ranks in the family GH-70. Furthermore, the synthesis of polysaccharides connected with controlled rates of glucosyl units linked in alpha-1,3 has never been described, and no such connected product existed hitherto on the market.

This type of bonds in alpha-1,3 confers resistance to the action of degradative enzymes such as glycoside hydrolases such as dextranases, glucoamylases, amylases and particularly the digestive enzymes of the human tract thus increasing the lifetime of the acceptor molecule to which they are associated, and conveying to the gluco-oligosaccharides new physicochemical and/or prebiotic properties, which prove interesting in terms of industrial applications.

Prebiotics are non-digestible food ingredients that arrive intact in the colon where they are then specifically metabolised by a certain, so-called “beneficial” category of the intestinal microbiota (human or animal). Compared with probiotics, prebiotics take precedence over the probiotics on the market for nutraceuticals, including through improved resistance to digestive barrier, potentially cheaper production costs and easier incorporation in food preparations.

In addition to their action on the intestinal flora, the so-called prebiotic molecules can also be metabolised by other commensal flora, such as skin or vaginal flora, and participate in the development of a so-called “beneficial” plant according to the same principles as those cited above.

These prebiotics include (from a perspective commercial) under the name of isomaltooligosaccharides all the glucose oligosaccharides composed mainly of α-1,6 bonds in the main chain and variable rates in α-1,4; α-1.3 and/or α-1,2 bonds. They are found naturally in various fermented products like miso, sake, soy sauce and honey. They can be industrially produced by starch hydrolysates by means of α-transglucosylases. In this case, the IMOS contain exclusively α-1,6 and α-1,4 bonds. However, these products can also be synthesised by acceptor reaction using the transglucosylases of the family GH-70. In this case, the product may also contain α-1,3 and α-1,2 bonds in addition to the α-1,6 and α-1,4 bonds, depending on the binding specificity of the glucansucrase used. These connections (α-1,3 or (α-1,2) are rare in nature, and impart to the molecules particularly interesting prebiotic properties, because they are even more difficult to digest than the other IMOS (including by certain pathogens that can partially recognise the α-1,6/α-1,4 IMOS).

The discovery made by the inventors makes it possible to consider the synthesis of a wide variety of polysaccharides having new and controlled structures and properties.

Thus, the inventors have demonstrated that the product obtained according to the reaction of their enzyme in the presence of sucrose and a linear dextran of molecular weight 1500 Da provides a polysaccharide having improved resistance to the action of digestive enzymes. The properties of this new polysaccharide as a prebiotic are therefore likely to be comparable to those of isomaltooligosaccharides or glucooligosaccharides connected in α-1,2.

Finally, such new polysaccharides may find use as prebiotic or as biopolymers, in the preparation of industrial formulations. Among the biopolymers, the polysaccharides (especially of plant origin, but also increasingly of microbial origin) can be used as texturising agents or stabilizers for various types of industrial products. An example of use of these biopolymers includes preparing readily degradable bioplastics. They could then replace the use of polymers of synthetic origin.

DETAILED DESCRIPTION OF THE INVENTION

A first object of the invention relates to an isolated polypeptide having the ability to form connections of glucosyl units in alpha 1,3 on an acceptor comprising at least one hydroxyl moiety and wherein said polypeptide comprises:

1) The pattern I of sequence SEQ ID no 1

2) The pattern II of sequence SEQ ID no 2

3) The pattern III of sequence SEQ ID no 3

4) The pattern IV of sequence SEQ ID no 4

or derivatives from one or several of said patterns; wherein said polypeptide furthermore has the aspartic residue (D) in position 5 of the pattern II (SEQ ID no 2), the glutamic acid residue (E) at position 6 of the pattern III (SEQ ID no 3) and the aspartic acid residue (D) in position 6 of the pattern IV (SEQ ID no 4).

These three amino acids can be readily identified by the skilled person, given the sequence homologies between enzymes with similar activities, such as representing the “catalytic triad” which is essential for the transglucosylase activity of the enzymes of the family GH 70 (LEEMHUIS et al, Journal of Biotechnology, vol. 163(2), p: 250-72, 2013).

In the polypeptide described above, the sequence SEQ ID no 1 is such that ADX₁VANQ with X₁ corresponds to F or Y; the sequence SEQ ID no 2 is such that SX₂RIDAISFVD with X₂ corresponds to M or I; the sequence SEQ ID no 3 is such that HX₃SIVEAX₄X₅X₆X₇ with X₃ corresponds to V or I, X₄ corresponds to P or S, X₅ corresponds to K or A, X₆ corresponds to G or D, X₇ corresponds to E or Q; the sequence SEQ ID no 4 is such that IVHAHDKDIQDX₈VX₉X₁₀ with X₈ corresponds to T or A, X₉ corresponds to S or I and X₁₀ corresponds to H or N.

Preferably, the pattern I has the sequence SEQ ID no 18 (ADFVANQ), the pattern II has the sequence SEQ ID no 19 (SMRIDAISFVD), the pattern III has the sequence SEQ ID no 20 (HISIVEAPKGE) and the pattern IV has the sequence SEQ ID no 21 (IVHAHDKDIQDTVIH).

Preferably, a polypeptide according to the invention is a polypeptide comprising the sequence SEQ ID no 5 (positions 636 to 1270 of the sequence SEQ ID no 9, domains A and C+, a part of the domain B) an orthologue, a derivative or a fragment thereof, preferably comprising the sequence SEQ ID no 6 (positions 586 to 1284 of the sequence SEQ ID no 9, comprising the entire domains A, B and C), an orthologue, a derivative or a fragment thereof.

Also advantageously, a polypeptide of the invention is a polypeptide comprising the sequence SEQ ID no 7 (positions 446 to 1356 of the sequence SEQ ID no 9, domains A, B, C and IV) an orthologue, a derivative or a fragment thereof, preferably comprising the sequence SEQ ID no 8 (positions 403 to 1606 of the sequence SEQ ID no 9, domains A, B, C, IV and V according to the homology with the transglucosylase GTF-180 of L. reuteri 180), an orthologue, a derivative or a fragment thereof.

Such a polypeptide may include the polypeptide truncated at its C-terminus (position 1313) of sequence SEQ ID no 13 (entire domains A, B and C).

Finally, a polypeptide of the invention is a polypeptide comprising or consisting of the sequence SEQ ID no 9 (entire sequence of the enzyme), an orthologue, a derivative or a fragment thereof.

The sequence SEQ ID no 9 corresponds to a polypeptide according to the invention, isolated from the strain Leuconostoc citreum NRRL B-742 (ATCC 13146), previously known as Leuconostoc mesenteroides NRRL B-742.

The term “orthologue” refers to a polypeptide having the same activity as the polypeptide of sequence SEQ ID no 9 of the strain Leuconostoc citreum NRRL742; wherein the polypeptide has an amino acid sequence that differs by at least one residue from the sequence SEQ ID no 9 and was isolated from a strain other than those mentioned above. More generally, by orthologue is meant a polypeptide having the same activity as the polypeptide of sequence SEQ ID no 9 isolated from a given bacterial strain which is derived from the same unique sequence as the polypeptide of sequence SEQ ID no 9 isolated from the strain Leuconostoc citreum NRRL B-742, which unique sequence is derived from the last common ancestor of these two strains.

Such orthologues include the sequences SEQ ID no 15 and SEQ ID no 17.

Advantageously, this orthologue was isolated from a bacterial strain belonging to the leuconostocaceae family, which includes the genera Leuconostoc, Oenococcus and Weissela Now this orthologue is preferentially isolated from a bacterial strain belonging to the genus Leuconostoc, or from the group consisting of Leuconostoc argentinum, Leuconostoc carnosum, Leuconostoc citreum, Leuconostoc gasicomitatum, inhae, Leuconostoc kimchii, and Leuconostoc pseudomesenteroides.

More simply, such an orthologue will have a sequence identity of at least 50 or 60% with the reference sequence including SEQ ID no 9, preferably at least 65%, 70%, 75%, 80% or 85%, and even more preferably at least 90%, 95%, 97%, 98% or 99% with the reference sequence.

By “derivative” is referred to a pattern or a polypeptide whose sequence has an identity percentage of at least 80%, for examples at least 85%, preferably at least 90%, and most preferably at least 95% with the reference sequence, namely a specific pattern (I, II, III or IV) or a polypeptide according to the invention, preferably with a polypeptide of sequence SEQ ID no 9.

Naturally, such a derivative of the polypeptide according to the present invention will have the enzymatic activity described above.

By “identity percentage between two polypeptide sequences” is meant the percentage of identical amino acids between two sequences to be compared, obtained with the best possible alignment of said sequences. This percentage is purely statistical and the differences between the two sequences are randomly distributed over the entire length of the amino acid sequences.

By “best possible alignment or optimal alignment” is meant the alignment for obtaining the highest percentage of identity. Sequence comparisons between two amino acid sequences are usually performed by comparing said sequences once they have been aligned in the best possible alignment; the comparison is then performed on comparison segments in order to identify and compare similarity regions. The best possible alignment to perform comparison can be performed using the local alignment algorithm developed by SMITH & WATERMAN (Ad. App. Math, vol. 2, p: 482, 1981), using the overall alignment algorithm developed by NEDDLEMAN & WUNSCH (J. Mol. Biol., vol. 48, p: 443, 1970), using the similarity method developed by PEARSON & LIPMAN (Proc. Natl. Acd. Sci. USA, vol. 85, p: 2444, 1988), using computer programs based on these algorithms (GAP, BESTFIT, BLAST P, BLAST N, FASTA, TFASTA, Genetics Computer Group, 575 Science Dr., Madison, Wis. USA), using multiple alignment algorithms MUSCLE (Edgar, Robert C., Nucleic Acids Research, vol. 32, p:1792, 2004) ou CLUSTAL (Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, Paern J, Lopez R. Nucleic acids research 2010 July, 38 Suppl: W695-9). To get the best possible alignment, we shall use preferably the BLAST program with the BLOSUM 62 matrix or the PAM matrix 30. The percentage identity is determined by comparing the two sequences aligned optimally, whereas said sequences may include additions or deletions in relation to the reference sequence so as to obtain the best possible alignment between these two sequences. The percentage identity is calculated by determining the number of identical positions between the two sequences, by dividing the number obtained by the total number of positions compared and by multiplying the result obtained 100 to generate the percentage identity between these two sequences.

By “fragment” is meant a polypeptide comprising the four units as described above and having a sequence of at least 150 amino acids, by way of example at least 450 amino acids, by way of example at least 700 amino acids, and particularly preferably a polypeptide of at least 1000 amino acids.

Preferably by fragment is meant a polypeptide comprising the domains A, B and C as the sequence SEQ ID no 13.

The terms “amino acid” and “amino acid” in the sense of the present invention correspond to any amino acid naturally present or to their residues. The amino acids may be identified either by their one-letter abbreviation, or by their three-letter abbreviation. (Asp D aspartic acid; Ile I isoleucine; Thr T threonine; Leu L Leucine; Ser S serine; Tyr tyrosine Y; Glu E glutamic acid; Phe F phenylalanine; Pro P proline; His H histidine; Gly G glycine; Lys K lysine; Ala A alanine; Arg R arginine; Cys C cystein; Trp W tryptophan; Val V valine; Gln Q glutamine; Met M methionine; Asn N asparagine). According to the present invention, the natural amino acids can be replaced by chemically modified amino acids.

The determination of the enzymatic activity of the polypeptide according to the invention can be determined by methods known to those skilled in the art, such as by use of the High Performance Liquid Chromatography Technique on reaction products with the polypeptide of the invention (MOULIS et al., J. Biol. Chem, 2006) or assay of reducing sugars by the method in dinitrosalycilic acid (SUMNER & HOWELL, 1935). More specifically, this enzymatic activity is expressed in glucansucrase units which represents the amount of enzyme which liberates one μmol of fructose per minute at 30° C. with a concentration of 100 g·L-1 sucrose and a buffer at pH 5.2 comprising 50 mM sodium acetate. This activity is preferably determined by measuring the initial rate of production of reducing sugars (fructose) by using the DNS method (SUMNER & HOWELL). To do this, a standard range of 0-2 g·L-1 of fructose is established. During kinetics, 100 μl of reaction medium are then sampled and the reaction is stopped by adding an equal volume of reagent. The samples were then heated for 5 min at 95° C., cooled in ice, diluted in half with water and the absorbance is read at 540 nm.

The polypeptide is “isolated” in the sense of the present invention inasmuch as it was removed from its original environment (the environment in which it is naturally located). For example, a polypeptide present naturally in a cell is not isolated. The same polypeptide separated from the other adjacent polypeptides within the cell in which it is naturally present, most commonly by a purification process, is isolated.

According to a preferred embodiment, the substrate of the polypeptide according to the invention is selected from the group consisting of α-D-glucopyranosyl fluoride, p-nitrophenyl α-D-glucopyranoside, α-D-glucopyranosyl α-L-sorofuranoside, lactulosucrose and sucrose, preferably sucrose which is the natural substrate.

The “sucrose” consists of an α-D-glucopyranosyl unit and a β-D-fructofuranosyl unit associated by a link (alphal-beta2). Hydrolysis of sucrose leads to a mixture of glucose and fructose.

By “glucosyl unit” is meant the residue resulting from the cleavage of sucrose, which is temporarily associated with the enzyme in the form of a β-glucosyl-enzyme and that is transferred to an acceptor comprising a hydroxyl moiety by forming a glycosidic bond with that hydroxyl moiety.

By “connection in alpha-1,3” is meant according to the invention a glucoside bond of condensation between the —OH function of the carbon located in position 1 of a first sugar and an —OH function of carbon located in position 3 of another sugar, said glucosidic bond being formed in an alpha configuration.

By “connection of glucosyl units in alpha-1,3” is meant a glucoside bond in alpha 1,3 between an acceptor according to the invention comprising at least one hydroxyl moiety and a glucosyl unit derived from the hydrolysis of sucrose by the polypeptide of the invention.

By “acceptor” according to the invention is meant any organic molecule comprising at least one free hydroxyl moiety (—OH), which acceptor is added to the reaction medium on top of the donor substrate of glucosyl units.

Such acceptor may be selected from the carbohydrate and non-carbohydrate acceptors.

Examples of non-carbohydrate acceptors include, but without being limited thereto, alcohols, polyols, phenolic compounds or still amino acids.

Examples of carbohydrate acceptors are preferably polysaccharides or more generally acceptor comprising glycosyl units.

According to a preferred embodiment, an acceptor according to the invention is a carbohydrate acceptor, preferably the latter will include glucosyl units.

Still according to a preferred embodiment, an acceptor of the invention includes polysaccharides. By polysaccharide is meant a sugar polymer containing n sugar units wherein n is an integer greater than or equal to 3.

Advantageously, these polysaccharides are composed exclusively of monomers of (glucans), and they may be linear or branched. These polysaccharides may correspond either to the α-glucans or to β-glucans.

The α-glucans are glucose polymers linked together in a position. Examples of α-glucans may include dextran (more than 50% of α-1,6 bonds in the main chain), dextran branched in α-1,2 (by the action of a α-1,2 “branching sucrase”), alternan (alternate α-1,6 and α-1,3 bonds in the main chain), mutan (more than 50% of α-1,3 bonds), reuteran (α-1,4 and α-1,6 bonds in the main chain), the starch (α-1,4 and α-1,6-glucan), amylopectine (α-1, 4 and α-1,6-glucan), was glycogen (α-1,4-glucan), amylopectin (α-1,4 and α-1,6-glucan) and p (α-1,4 and α-1,6-glucan).

The β-glucans are glucose polymers linked together in β position. Examples of β-glucans include cellulose (β-1,4-glucane), curdlan (β-1,3-glucane), laminarin (β-1,3-et (β-1,6-glucan), lentinan (β-1,6:β-1,3-glucan), pamylon, pleuran (β-1,3-et β-1,6-glucan) and zymosan (β-1,3-glucan).

Now, a preferred acceptor would be an α-glucan such as amylose, starch, amylopectin, dextran, glycogen or pullulan, dextrans branched in α-1,2, alternan, mutan and reuteran.

According to a particularly preferred embodiment, an acceptor according to the invention is a dextran, a polymer whose glucosyl units are connected together by alpha 1-6 bonds. This polymer may also include branches consisting of alpha-1,2 or 1,3 or 1,4 bonds.

Dextrans used as an acceptor according to the invention have a molecular weight (MW) between 300 and 10⁹ Dalton (Da), preferably between 10³ and 10⁹ Da and even more preferably between 1000 and 2·10⁶ Da.

The advantage of the invention lies in that the polypeptide as described above is responsible for the formation of connecting glucosyl units in the alpha-1,3 position of an acceptor.

Preferably, the polypeptide according to the invention has the ability to form connections of glucosyl units in alpha 1,3 on an acceptor at a rate between 1 and 50%, preferably between 5% and 40%, and more preferably still between 10 and 40%.

Even more preferably, the polypeptide according to the invention has the ability to form connections of glucosyl units in alpha 1,3 on an acceptor at a maximum rate of 50%.

Another object of the invention concerns an isolated polynucleotide encoding a polypeptide as defined above, a fragment or a derivative thereof.

According to the invention, said polynucleotide is a DNA or RNA molecule.

By “polynucleotide” is meant broadly a DNA molecule such as for instance a cDNA (complementary DNA) or genomic or synthetic DNA, or an RNA molecule, such as a messenger RNA or synthetic RNA, as well as analogues of DNA or RNA containing non-natural nucleotide analogues, non-natural internucleotide linkages, or both. Preferably, said polynucleotide is a DNA molecule. The polynucleotides may have any topological conformation, such as linear or circular.

In a preferred embodiment of the invention, said polynucleotide is defined by the sequence SEQ ID no 10.

Another object of the invention relates to an expression vector comprising a polynucleotide as described above.

By “vector” is meant any vehicle capable of facilitating the transfer of a polynucleotide into a cell. In general, the vectors of the invention include, without limitation thereto, plasmids, cosmids, phagemids or other vehicles derived from viral or bacterial sources that have been manipulated for insertion or incorporation of a nucleotide sequence.

The choice of vectors usable in the context of the present invention is vast. They can be cloning and/or expression vectors. In general, they are known to those skilled in the art and many of them are commercially available but it is also possible to construct them or to modify them by genetic engineering techniques.

Preferably, the vectors according to the invention are plasmid vectors, also known as plasmids. The plasmids were widely described in the prior art and are well known to the skilled person (see eg SANBROOK et al., “Molecular Cloning: A Laboratory Manual,” Second Edition, Cold Spring Harbor Laboratory Press, 1989). Examples include the most commonly used plasmids such as pBR322, pUC18, pUC19, pRC/CMV, SV40 and pBlueScript, pET-53-DEST, pET-55-DEST, pBAD49-DEST, pET-60-DEST. The plasmids can be designed by the use of restriction enzymes and ligation reactions or recombination systems to remove or insert specific DNA fragments. The plasmids in which the nucleotide sequences are inserted, are in the form of a single or double stranded, linear or circular DNA.

Preferably, a vector implemented in the context of the present invention contains a replication origin ensuring the initiation of replication in a producing cell and/or a host cell. It also contains the elements necessary for the expression of a polynucleotide of the invention, such as a promoter and a terminator. Examples of suitable promoter according to the invention include, but are not limited to, T7, araBAD, pLac, POX2, AOX (alcohol oxidase) promoters.

It may further comprise one or more selection gene(s) to select or identify the cells transformed or transfected with said vector (complementation of an auxotrophic mutation, a gene encoding resistance to an antibiotic . . . ). It can also comprise additional elements improving its maintenance and/or its stability in a given cell (cer sequence which promotes the monomeric maintenance of a plasmid, integration sequences into the cell genome).

The vector of the invention may optionally be associated with one or more substances improving the efficiency of transformation or transfection and/or the stability of the vector. These substances are widely documented in the literature accessible to those skilled in the art. By way of illustration but without limitation, they may be polymers, in particular cationic lipids, liposomes, nuclear proteins or neutral lipids. These substances may be used alone or in combination. One possible combination is a plasmid recombinant vector associated with cationic lipids (DOGS, DC-CHOL, spermine-chol, spermidine-chol, etc.) and neutral lipids (DOPE).

The polynucleotide, preferably the DNA molecule, in the expression vector is operatively linked to a promoter to direct the synthesis of RNA. For example, developers may be eukaryotic or prokaryotic promoters such as CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retroviruses, and mouse metallothionein-I. The expression vector also contains a ribosome binding site for initiating the translation and a transcription vector. The vector should also include enhancer sequences of the expression.

By “operably linked to a promoter” is meant the link through which a promoter is located contiguously to the polynucleotide of the invention for controlling the expression of said sequence.

The term “promoter” is well known to those skilled in the art and refers to a DNA region adjacent to a gene to which RNA polymerase binds to start the transcription.

Another object of the invention also relates to a transformed host cell comprising a vector according to the invention.

For the purposes of the present invention, such a cell consists of any cell which can be transformed or transfected by an inventive vector as described above.

The cell is called “host cell” and may be a prokaryotic cell or a eukaryotic cell.

Preferably, the host cell transformed according to the invention is a prokaryotic cell selected from the group consisting of eubacteria, archaebacteria and cyanobacteria.

The bacterial expression systems can be used in the context of the present invention. Examples of bacterial host cells include bacteria of the genera Escherichia (e.g. Escherichia coli), Pseudomonas (e.g. Pseudomonas fluorescens or Pseudomonas stutzerei), Proteus (e.g. P. mirabilis), Ralstonia (such as Ralstonia eutropha), Streptomyces, Staphylococcus (eg Streptomyces carnosus), Lactococcus (eg Lactoccocus lactis), Bacillus (eg Bacillus subtilis, Bacillus megaterium or Bacillus licheniformis), Lactobacillus or Leuconostoc etc.

More preferably, the host cell transformed according to the invention is a eukaryotic cell selected from the group consisting of animal, fungal, yeast, and plant cells.

Yeast cells are also hosts cells which can be suitable in the scope of the invention. Examples of yeast host cells which may be used include, but are not limited to, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Klyveromyces lactis, Yarrowia lipolytica, Hansenula polymorpha or Pichia pastoris.

Fungal expression systems are also conceivable within the scope of the present invention, such as Aspergillus Niger, Chrysosporium lucknowense, Aspergillus (e.g. Aspergillus oryzae, Aspergillus Niger, Aspergillus nidulans, etc.), Podospora anserina or Trichoderma reesei.

Other expression systems such as mammalian expression systems can also be used in the context of the invention, such as the NSO, CHO, BHK cell lines, transgenic systems of mammalian origin, but also the cells insect or viral expression systems such as bacteriophage M13, T7 or λ or the expression systems Baculovirus

Preferably, the host cell according to the present invention is a prokaryotic cell.

The terms “transformed host cell,” “transformed” and “transformation” as defined in the present invention refer to the introduction of DNA into a cell. The introduction of a polynucleotide or a vector as described in the present invention into the host cell can be effected by methods well known to those skilled in the art such as the electroporation, heat shock on competent cells, recombination, conjugation, transfection by PEI, by calcium phosphate, transfection by DEAE dextran or still electroporation.

According to another object, the invention provides a composition comprising at least one polypeptide, one polynucleotide, one vector or one host cell as described above.

Another object of the invention relates to a method of producing a polypeptide as described above, said method comprises the steps of:

-   -   a) inserting a polynucleotide or a vector as described         previously in a host cell;     -   b) culturing said cell obtained in step a); and     -   c) extracting the polypeptide of the invention from the culture         obtained in step b).

Step (a) of introducing a polynucleotide or a vector as described above into the host cell is accomplished by well-known processing techniques to those skilled in the art, such as transfection, lipofection, transformation by lithium acetate, biolistic transformation, transformation by PEI, protoplast fusion, liposome transformation, transformation by Agrobacterium tumefaciens, or still viral or adenoviral infections.

Extraction of the polypeptide of the invention is made from the culture of step (b) and produced by techniques well-known to those skilled in the art. If the host organism produces the polypeptide extracellularly, the culture supernatant is recovered by centrifugation and may be directly used for implementing the syntheses of products. If the expression is intracellular, the cells are centrifuged, concentrated, then lysed by means of lysozyme and detergents or crushed ultrasonically or treated by mechanical breakage using glass beads or FRENCH press.

If necessary, the extraction can consist of a purification of the polypeptide may be performed by affinity chromatography for chelating metals such as nickel or cobalt and using a tag (label) of type “Histidine” (6 successive histidines) fused to the polypeptide sequence as described above.

Another object of the invention relates to a process for producing acceptors connected to glucosyl units in alpha 1,3 comprising a rate of connections of such glucosyl units in alpha 1,3 between 1 and 50%, said method comprising the steps of:

mixing in a reaction medium a polypeptide according to the invention, of a substrate of said polypeptide and an acceptor comprising at least one hydroxyl moiety; and

ii) incubating said mixture obtained in step i) so as to obtain the connection of glucosyl units in alpha-1,3 on said acceptor.

The term “acceptor connected to glucosyl units in alpha 1,3” according to the invention an acceptor as defined above which are attached by the action of a polypeptide according to the invention of glucosyl units derived from the hydrolysis of the substrate.

According to a preferred embodiment, an acceptor connected to glucosyl units in alpha-1,3 according to the invention is selected from the group consisting of polysaccharides, preferably glucans, in particular α-glucans such as α-1,6 glucans (eg dextran).

According to a preferred embodiment and as described above, the substrate of the polypeptide according to the invention is selected from the group consisting of α-D-glucopyranosyl fluoride, p-nitrophenyl α-D-glucopyranoside, α-D-glucopyranosyl, α-L-sorofuranoside, lactulosucrose and sucrose, preferably sucrose.

According to a preferred embodiment, the method according to the invention allows to control the rate of alpha-1,3 connections of the acceptor by directly varying the ratio between the substrate concentration and the acceptor concentration.

According to a preferred embodiment of the invention, said method is characterised in that it is intended to obtain an acceptor connected to glucosyl units in alpha 1,3 at a rate between 1% and 50%, preferably between 5 and 40% and more preferably still between 10 and 40%. This variation is possible depending on the ratio between the concentration of the substrate to that of the free hydroxyl moieties of the acceptor molecule, or the ratio between the mass concentration of the substrate to that of the acceptor in the case of dextran and sucrose.

Advantageously, the concentrations of acceptor and substrate are adjusted so as to obtain a degree of connection between 35 and 50%, preferably between 35 and 40%. Typically, this degree of connection is obtained with a ratio greater than or equal to 1.

Advantageously, the concentrations of acceptor and of substrate are adjusted so as to obtain a degree of branching between 20 and 35%. Typically, this level of connection is achieved with a ratio of between 0.5 and 1.

Advantageously still, the concentrations of acceptor and substrate are adjusted so as to obtain a degree of branching less than 20%. Typically, this rate of connection is obtained with a ratio less than 0.5.

According to the invention, the rate of connection in alpha-1,3 obtained in the context of this method is considered in relation to all the sites available on said acceptor.

According to a particular embodiment, said method according to the invention further comprises a step c) of purification of acceptor connected to glucosyl units in alpha 1,3.

Still according to a particular embodiment, the method of the invention comprises a step d) of characterisation of the acceptors connected to glucosyl units in alpha-1,3 of the invention. Such a characterisation step may be performed by various methods well-known to those skilled in the art.

By way of example, high performance liquid chromatography technique (HPLC), mass spectrometry, nuclear magnetic resonance spectrometry (NMR), chemical techniques such as methylation and acetolysis or ELISA with monoclonal antibodies specific for alpha-1,3 bonds will be used.

Another object of the invention relates to an acceptor connected to glucosyl units in alpha-1,3 obtainable by the process as described above.

Said acceptor may not be a dextran.

Also advantageously, the rate of connection of said acceptor is less than 50%, preferably less than 40%.

The present patent application is also intended to cover the various possible uses of a polypeptide, a polynucleotide, a vector, a host cell and/or a composition of the invention as described above.

Thus, another object of the invention relates to the use of a polypeptide, a polynucleotide, a vector, a host cell and/or a composition according to the invention for the production of acceptors connected to glucosyl units in alpha-1,3.

Preferably, said acceptors are connected to glucosyl unit in alpha 1,3 at a rate between 1 and 50%, preferably between 5 and 40%, and most preferably still between 10 and 40%.

This patent application is also intended to cover the various possible uses of an acceptor connected to glucosyl units in alpha-1,3 of the invention.

The invention thus relates to the use of an acceptor connected to glucosyl units in alpha-1,3 produced from a polypeptide of the invention as an agent charge, thickener, emulsifier, texturising agent and/or stabiliser in the preparation of industrial food, cosmetic, agrochemical, petrochemical and pharmaceutical formulations.

These applications consist of the use of these acceptors connected to glucosyl units in alpha-1,3 as biopolymers.

Examples of industrial formulations of the invention include without limitation bioplastics, but also the food formulations, such as bakery products, as well as formulations in the pharmaceutical sector.

Other examples of industrial formulations also include formulations for the construction, paint, paper, textile, plant protection, water treatment, oil industries.

The invention also relates to the non-therapeutic use of an acceptor connected to glucosyl units in alpha-1,3 as an agent prebiotic.

The acceptors connected to glucosyl units in alpha-1,3 produced according to the invention has the advantages of a better resistance to the digestive barrier, a better stability, potentially cheaper production costs and greater ease to be incorporated in food preparations.

Prebiotics are non-digestible food ingredients that arrive intact in the colon where they are then specifically metabolised by a certain, so-called “beneficial” category of the intestinal microbiota (human or animal).

Non-limiting examples of prebiotics effects include improved intestinal transit in animals and humans, improved absorption of minerals such as calcium, magnesium, zinc or even iron, reduced intestinal inflammation or still reduced growth of pathogens.

EXAMPLES Example 1 Screening of New Enzymes in L. citreum NRRL B-742

After sequencing of the genome of the strain L. citreum NRRL B-742, a gene proved particularly original. Indeed the corresponding putative protein was found to have a sequence having a maximum of only 54% identity with the putative glycoside hydrolase Leuconostoc fallax KCTC 3537 whose sequence is available in the database, and referenced by the NCBI under number ZP_08312597. Now, any other protein sequence with significant identity could be identified.

This gene encodes a putative transglucosylase of 1888 amino acids, having the characteristic catalytic triad DED and the 4 conserved regions usually described in transglucosylases of family 70. The schematic representation of the protein is shown in FIG. 1 (based on the alignment of protein sequences with GTF180) with 5 domains: i) domain V (403-446 and 1356 to 1800), ii) domain IV (446-586 and 1284-1356), iii) domain A (catalytic) (636-899, 1052-1191 and 1231-1270), iv) domain B (586-636, 1191-1231 and 1270-1284) and v) domain C (899-1052). The catalytic amino acids (DED) are indicated with a star in the primary structure and are shown in bold and red in the different patterns II, III and IV.

Now, particularly original protein patterns were identified upstream and downstream of amino acids of the catalytic triad, usually in highly conserved regions (see table 1).

Due to the originality of this putative transglucosylase, it was decided to initiate cloning so as to begin its biochemical characterisation.

TABLE 1  Sequence Alignment of conserved regions of the catalytic heart of the new transglucosylase  (called α-1,3BrS in the table) and orthologues identified (from Leuconostoc fallax KCTC3537  and Leuconostoc citreum LBAE E16) with characterised enzymes and with known specificity of links Speci- GenBank Pattern II Pattern III Pattern IV Pattern I ficity AAC6306 GtfI  449 SIRVDAVDNVD  486 HVSIVEAWSDN  559 FARAHDSEVQDLIRD  931 ADWVPDQ ▭-1,3 3.1 [Sd] AAA8858 GtfB 1011 SIRVDAVDNVD 1048 HLSILEAWSDN 1120 FIRAHDSEVQDLIAD 1488 ADWVPDQ 8.1 [Sm] BAA2611 GtfSI  473 SIRVDAVDNVD  510 HLSILEAWSDN  583 FIRAHDSEVQDLIRD  954 ADWVPDQ 4.1 [Sm] AAU0801 GtfA 1020 SVRVDAPDNID 1056 HINILEDWNHA 1128 FVRAHDNNSQDQIQN 1508 ADWVPDQ ▭-1,4/ 5.1 [Lr] ▭-1,6 AAY8692 GtfO 1020 SVRVDAPDNID 1056 HINILEDWNSS 1128 FIRAHDNNSQDQIQN 1508 ADWVPDQ 3.1 [Lr] CAB6591 Asr  631 GIRVDAVDNVD  668 HLSILEDWNGK  762 FVRAHDYDAQDPIRK 1168 ADWVPDQ ▭-1,6/ 0.2 [Lm]   ▭-1,3 ABQ8359 GtfW  748 GFRVDAADNID  785 HLVYNEGYHSG  568 FVTNHDQR-KNVINQ 1216 EDLVMNQ ▭-4,6 7.1 [Lr] AAU0800 GtfML4 1012 GFRVDAADNID 1049 HLSYNEGYHSG 1121 FVTNHDQR-KNLINR 1479 EDIVMNQ 3.2 [Lr] ABF8583 DsrCB4  526 GIRVDAVDNVD  563 HLSILEDWSHN  636 FVRAHDSEVQTVIAQ 1001 ADWVPDQ ▭-1,6 2.1 [Lc] CAB7656 DsrC  498 GIRVDAVDNVD  535 HLSILEDWSHN  608 FVRAHDSEVQTVIAQ  973 ADWVPDQ 5.1 [Lm] AAD1095 DsrS  547 GIRVDAVDNVD  584 HLSILEDWSHN  657 FVRAHDSEVQTVIAQ 1023 ADWVPDQ 2.1 [Lm] AAU0800 GTF180 1021 GIRVDAVDNVD 1058 HINILEDWGWD 1131 FVRAHDSNAQDQIRQ 1503 ADWVPDQ 1.1 [Lr] CAD2288 GBD- 2206 SIRIDAVDFIH 2243 HISLVEAGLDA 2317 IIHAHDKGVQEKVGA 2688 ADVVDNQ ▭-1,2 3.1 CD₂ [Lc] BrS  667 SMRIDAISFVD  704 HISIVEAPKGE  783 IVHAHDKDIQDTVIH 1182 ADFVANQ ▭-1,3 [Lc] BrS   734 SIRIDAISFVD  771 HVSIVEASADQ  845 IVHAHDKDIQDAVSN 1232 ADYVANQ ▭-1,3 [L. fallax] BrS   667 SMRIDAISFVD  704 HISIVEAPKGE  783 IVHAHDKDIQDTVIH 1182 ADFVANQ ▭-1,3 [L. citreum E16]

Example 2 Production of a New Enzyme in E. coli

The gene encoding this enzyme has been cloned into several vectors (pET 53, 55, 49 and 60) commercially available from NOVAGEN or INVITROGEN, and expressed in different various of E. coli (TOP10, BL21AI, BL21 DE3 Star, Arctic Express DE3).

This cloning resulted in a consistent production of the protein. This production has helped initiate the experiments of biochemical characterisation to clarify the catalytic properties of the identified enzyme.

Simultaneously, a truncated form of the signal peptide and C-terminal, APS AC-1313 SEQ ID no 12 and SEQ ID no 13 for the nucleic and protein sequences, respectively) of the protein has been cloned and expressed in the strain of E. coli BL21 DE3 star, allowing again a significant expression of the protein; which expression has proved almost twice higher than that of the wild-type protein.

Example 3 Reaction of a Polypeptide According to the Invention with Sucrose, a Dextran-Type Acceptor and the Enzyme Object of the Invention and Analysis of the Products of this Reaction

To characterise the functional properties of this putative transglucosylase, the enzyme was first implemented on sucrose alone, a natural substrate of enzymes of the GH70 family.

Unexpectedly, the chromatographic analyses (HPAEC-PAD, HPSEC) showed that the enzyme alone is only capable of hydrolysing the substrate in equimolar amounts of glucose and fructose. Now and from sucrose alone, this enzyme showed no ability to produce polymers of glucosyl units, as well as its truncated form.

It is interesting to note that to date, bioinformatic analyses on the primary structure of the GH of the family 70 would not predict this feature (structural determinants governing the ability—or not—of a transglucosylase polymerising are not yet known).

While nothing presaged that this protein had still an activity, the latter (as well as its truncated form) was also incubated in the presence of sucrose and a linear dextran (glucan composed exclusively of α-1,6 bonds) of a molecular weight of 1500 Da.

We incubated for 16 h at 30° C., enzyme in sucrose (from 25 g/L to 170 g/L) in the presence of dextrans of variable molecular weight (from 1500 Da to 2·10⁶ Da) and of varying concentration of 30 g/L to 100 g/L; the sucrose/acceptor (M/M) ratio varies depending on the desired connection rate in α-1,3. The reaction medium was buffered with a solution with final sodium acetate with 50 mM, pH 5.2. A sample at initial and final times of the reaction was conducted, heated at 95° C. for 5 minutes to stop the reaction and analysed by various chromatographic (HPAEC-PAD, HPSEC) and structural (proton NMR) techniques.

More specifically, monosaccharides, disaccharides, and small oligosaccharides (degree of polymerisation less than 20) were separated and quantified by HPAEC-PAD (High Performance Anion Exchange Chromatography with Pulsed Amperometric Detection) on column Dionex CarboPac PA-100. A sodium acetate gradient of 6 to 300 mM in 36 min, containing 150 mM of sodium hydroxide used to separate glucose, fructose, sucrose, leucrose, isomaltooligosaccharides, etc. Standard ranges of 5, 10, 15 and 20 mg·kg-1 of these sugars were performed to allow quantification. These samples were diluted for a total sugar concentration of 25 mg·kg-1.

Analyses by HPSEC (High Performance Size Exclusion Chromatography) were used to estimate the molecular weight of oligosaccharide populations or of polymers synthesised during the reactions. The separation was done using two columns SHODEX (OH-Pack SB-805 and 802.5) arranged in series. Solutions of 1, 2.5, 5 and 10 gL-1 sucrose, fructose, maltoheptaose, Dextran 11.3 kDa, 68.4 kDa, 503 kDa, 2000 kDa served as benchmarks. The samples were diluted 10 times to reach a maximum concentration of 10 g·kg-1. A solution of 0.45 M NaNO3+1% (v/v) ethylene glycol in 0.3 mL-min-1 is used as an eluent, and the samples should be diluted in the mobile phase. Column and precolumn were maintained at 70° C., detection is performed by refractometry.

For the NMR analyses, the synthesised polymers were stored at −80° C. overnight and then be freeze-dried (CHRIST ALPHA apparatus 2-4). 10 mg of the powder obtained are then dissolved in 0.5 mL of deuterated water and analysed by proton NMR. The 1H NMR spectra were acquired on a spectrometer BRUKER AVANCE (500 MHz). The data were then treated with the TOPSPIN 3.0 software.

FIG. 2 shows the HPAEC-PAD profiles of a reaction using dextran 1500 Da as an acceptor.

FIG. 3 shows the profile NMR of dextran 1500 Da obtained at the end of incubation.

FIG. 4 shows the HPAEC-PAD profiles of endodextranase digestion of the products of the sucrose+dextran 1500 Da acceptor reaction (to=1500 Da dextran connected in α-1,3).

While no polymerisation was observed in the presence of sucrose, the results revealed a characteristic modification of dextran. A more detailed analysis of chromatographic results and structural analyses by proton NMR show the synthesis of branches in α-1,3 on the acceptor molecule (FIGS. 2 and 3). In particular, the reaction product is resistant to the action of an endodextranase, an enzyme specific for the hydrolysis of α-1,6 bonds (FIG. 4). More broadly, these results suggest a resistance to the action of digestive enzymes, and therefore the existence of prebiotic properties comparable to those of isomaltooligosaccharides or gluco-oligosaccharides connected in α-1,2 (GOFFIN et al. Crit Rev. Food Sci. Nutr., vol. 51(5), p:394-409, 2011; SARBINI et al., Appl. Environ. Microbiol., vol. 77(15), p:5307-15, 2011).

The enzyme, as its truncated form, is particularly effective shown also to catalyse the transfer of glycosyl residues on isomaltooligosaccharides since the addition of dextran 1500 Da as an acceptor molecule in the reaction medium has the effect of multiplying the activity of the enzyme by a factor of 26 (compared to the activity measured on sucrose alone).

Finally, these results demonstrate that the identified protein is responsible for the connections in α-1,3 of the glucan corresponding to the proportion S and that a single enzyme, as was previously believed, is not the initiator of the synthesis of this specific glucan. Because of this activity, the corresponding gene encoding an “enzyme responsible for glucosylations specific by connection in α-1,3” is named α-1,3BrS.

Example 4 Influence of Changes in Concentration of Substrate/Acceptor on the Number of Connections Obtained in Alpha-1,3

Additional experiments have also shown that by varying the sucrose concentration relative to the concentration of dextran 1500 Da (donor/acceptor ratio), it is possible to control the degree of connection in α-1,3 of this the small dextran.

FIG. 5 shows the control of the rate of α-1,3 bonds according to the sucrose/dextran 1500 Da ratio (using mass concentrations).

FIG. 6 also shows the control of the rate of α-1,3 bonds according to the sucrose/dextran 1500 Da ratio but with the truncated enzyme.

The results show that at a sucrose/Dextran 1500 ratio (equivalent to a substrate/hydroxyl moiety ratio) greater than or equal to 1, we arrive at a degree of substitution of about 40% and approaches 50% by increasing the substrate concentration. Now, by modulating this report, we come to reduce the substitution rate. Thus, for a 1/2 ratio, the substitution rate is slightly lower than 25%, and a ratio of 1/3, the rate of substitution rises and is slightly below 15%.

Note that the inventors on the same substrate with the truncated form came to the same results (FIG. 6), confirming that the truncated enzyme retains the same specificity as the whole shape.

Example 5 Dextran Acceptors

→ Moreover, the enzyme and its truncated form have proved capable of carrying out such connection reactions in α-1,3 over a wide range of higher molecular weight dextrans. Tests were performed out on particular dextran 68.4 kDa, 503 kDa and 2×10⁶ Da. Based on proton NMR analyses, the high molecular weight dextrans have 50% of α-1,3 bonds (FIGS. 7 and 8). Here again we find the comb-like structure described in the '80s in the work on the native glucan produced by the strain.

FIGS. 7 and 8 show the NMR spectrum of dextran 68.4 kDa connected in α-1,3 obtained with the whole enzyme and the truncated enzyme respectively.

These results show that the α-1,3BrS is therefore able to recognise and connect many dextrans having a molecular weight between 1.5 and 2×10⁶ kDa. We can therefore offer a range of products from small prebiotic gluco-oligosaccharides to high molecular weight polymers, with rates controlled (like) of connections in α-1,3.

Example 6 Identification of an Orthologue in L. citreum

With this characterisation, the inventors sought orthologues to this enzyme, which allowed identification of such an orthologue of this enzyme in the genome of the strain L. citreum LBAE E16 (SEQ ID no 14 and SEQ ID no 15 for the nucleic and protein sequences of this orthologue respectively).

A comparative analysis of the newly identified with the previous sequence has revealed that they share 98% identity for the complete sequence with an identity of 100% with respect to the patterns I to IV of the catalytic heart.

Example 7 Identification of an Ortholog in L. fallax

The identification of an orthologue opened the way to research on other orthologues in other species, which has allowed the inventors to identify at the strain KCTC 3537 Leuconostoc fallax a protein (SEQ ID no 17) having an overall identity of about 54% with the protein sequence of α-1,3 BrS, which rises to 68% when we focus on the catalytic domains A, B and C.

An analysis of the catalytic units I, II, III and IV shows a slight discrepancy regarding the pattern III

Pattern II  Pattern III  Pattern IV  Pattern I  (SEQ ID no) (SEQ ID no) (SEQ ID no) (SEQ ID no) α-1,3 BrS SMRIDAISFVD HISIVEAPKGE IVHAHDKDIQ ADFVANQ  (19) (20) DTVIH (21) (18) GH L.fallax SIRIDAISFVD HVSIVEASADQ IVHAHDKDIQ ADYVANQ (23)  (24) DAVSN (25) (22) Identity (%) 90 54,5 80 85

As above, the inventors conducted a cloning of this putative hydrolase glycoside and its recombinant expression in E. coli.

To do so, the inventors have previously made a synthetic gene (SEQ ID no 16) by codon optimisation of the wild-type gene, to facilitate recombinant expression of the protein in E. coli BL21 star DE3 as before. The production of the protein allowed to obtain an amount of protein for characterisation (output 2.5 times greater than that obtained for α-1,3 BrS).

Brought into contact with sucrose only, the enzyme revealed, as for the α-1,3 BrS, its inability to polymerise the glucosyl units. Now, as for the α-1,3 BrS, it showed its ability to make connections in α-1,3 on a dextran 1500 Da with a connection rate of 37%.

Example 8 Development of a Method in One Single Step for the Production of Oligosaccharides with Connections Controlled in α-1,3

This process involves the implementation of a polymerase of the family GH-70 coupled with the action of the enzyme α-1.3 BrS on sucrose alone.

In its implementation, the method is tested on a variable proportion of the two enzymes.

The products formed from the enzymatic reaction are analysed by chromatography (HPAEC-PAD, HPSEC to determine the size of the oligosaccharides produced) and NMR of the proton (determination of the proportion of α-1,3 bonds).

Example 9 Assessment of Physico-Chemical Properties of Very High Molecular Mass Glucans with Controlled Content of α-1,3 Bonds

Different high molecular weight glucans are incubated in the presence of the α-1,3 BrS enzyme. The physicochemical properties of the resulting glucans are investigated, in particular by thermogravimetric analysis, by determining the glass transition temperature, and rheological analysis (see IRAGUE et al, Biomacromolecules, 2012).

Example 10 Assessment of Physico-Chemical Properties of Very High Molecular Mass Glucans with Controlled Content of α-1,2 and α-1.3 Bonds

Different very high molecular mass glucans are incubated in the presence of the enzyme α-1,3 BrS and of the enzyme GBD-CD2 (BRISON and al., 2009) which shows a connecting activity in α-1,2. The physicochemical properties of the resulting glucans are investigated, in particular by thermogravimetric analysis, by determining the glass transition temperature, and rheological analysis (see IRAGUE et al, Biomacromolecules, 2012).

Example 11 Assessment of Physico-Chemical and Prebiotic Properties of Oligosaccharides with a Controlled Content in α-1,2 and α-1.3 Bonds

Isomaltooligosaccharides are incubated in the presence of the enzyme α-1,3 BrS and of the enzyme GBD-CD2 which shows a connecting activity in α-1,2. Prebiotics and physicochemical properties of the resulting glucans are investigated.

Example 12 Evaluation of the Prebiotic, Nutritional Properties and of the Metabolic Effects of Oligosaccharides Connected in α-1.3

These properties are tested for different oligosaccharides connected with the enzyme α-1,3 BrS.

Example 13 Screening of a Library Acceptor

The enzyme α-1,3 BrS is put in the presence of its natural substrate (sucrose) and a panel of different acceptors, including dextrans connected in α-1.2 (BRISON et al., 2009), of mutans, of alternans, of reuterans, of fructans and of fructooligosaccharides, of polyphenols, of flavonoids, of amino acids. The reaction products are analysed by various chromatographic techniques (mass spectrometry, HPAEC-PAD) and by NMR.

These experiments have already shown that this enzyme allows the glycosylation of oligosaccharides such as the fructoologosaccharides (FOS) and xylooligosaccharides (XOS)

Example 14 Screening of a Donor Library

The enzyme α-1,3 BrS is implemented on various analogues of sucrose (DAUDE et al, 2012) which can serve as donor of glucosyl units. 

1. An isolated polypeptide having the ability to form specifically connections of glucosyl units in alpha-1,3 on an acceptor comprising at least one hydroxyl moiety and characterised in that said polypeptide comprises: i) the pattern I of sequence SEQ ID no 1 ii) the pattern II of sequence SEQ ID no 2 iii) the pattern III of sequence SEQ ID no 3 iv) the pattern IV of sequence SEQ ID no 4 or derivatives of one or more of said domains having at least 80% identity with them; wherein said polypeptide furthermore has the aspartic residue (D) in position 5 of the pattern II (SEQ ID no 2), the glutamic acid residue (E) at position 6 of the pattern III (SEQ ID no 3) and the aspartic acid residue (D) in position 6 of the pattern IV (SEQ ID no 4).
 2. The isolated polypeptide according to claim 1, characterised in that said polypeptide comprises the sequence SEQ ID no 6, an orthologue, a derivative, or a fragment thereof.
 3. The polypeptide according to claim 1, characterised in that said polypeptide comprises or consists of the sequence SEQ ID no 9, an orthologue, a derivative, or a fragment thereof.
 4. The polypeptide according to claim 1, characterised in that said orthologue is selected from the group comprising the sequences SEQ ID no 15 and SEQ ID no
 17. 5. An isolated polynucleotide encoding a polypeptide according to claim 1, preferably said polynucleotide is defined by the sequence SEQ ID no
 10. 6. An expression vector comprising a polynucleotide as defined in claim
 5. 7. A transformed host cell including an expression vector as defined in claim
 6. 8. A composition comprising at least one polypeptide as defined in claim 1, a polynucleotide encoding said polypeptide, a vector comprising said polynucleotide or a transformed host cell including said vector.
 9. A method of producing a polypeptide as defined in any one of claim 1, said method including the steps of: a) inserting a polynucleotide encoding said polypeptide or a vector comprising said polynucleotide into a host cell; b) culturing said cell obtained in step a); and c) extracting the polypeptide from the culture obtained in step b).
 10. A process for producing acceptors connected to glucosyl units in alpha 1,3 comprising a rate of connections of such glucosyl units in alpha 1,3 between 1 and 50%, said method comprising the steps of: i) mixing in a reaction medium a polypeptide as defined in claim 1, a substrate of said polypeptide and an acceptor comprising at least one hydroxyl moiety; and ii) incubating said mixture obtained in step i) so as to obtain the connection of glucosyl units in alpha-1,3 on said acceptor.
 11. The method according to claim 10, characterised in that the concentrations of substrate and of acceptor are adjusted so to get a connection rate between 35 and 50%.
 12. The method according to claim 10, characterised in that the concentrations of substrate and of acceptor are adjusted so to get a connection rate of 20 to 35%.
 13. The method according to claim 10, characterised in that the concentrations of substrate and of acceptor are adjusted so to get a connection rate lower than 20%.
 14. The method according to claim 1, characterised in that said acceptor connected to glucosyl units in alpha-1,3 is selected from the group of polysaccharides, preferably glucans, including α-glucans such as dextran, dextrans branched in α-1,2, alternans, mutans, reuterans, starch, amylopectin, amylose, glycogen and pullulan.
 15. The method according to claim 10, characterised in that the substrate is selected from the group comprising α-D-glucopyranosyl fluoride, p-nitrophenyl α-D-glucopyranoside, α-D-glucopyranosyl, α-L-sorofuranoside, lactulosucrose and sucrose.
 16. An acceptor connected to glucosyl units in alpha-1,3 likely to be obtained by the method according to claim
 11. 17. A method for the production of acceptors connected to glucosyl units in alpha-1,3, comprising: i) mixing in a reaction medium: a polypeptide as defined in claim 1, of a polynucleotide encoding said polypeptide, of a vector comprising said polynucleotide, of a host cell including said vector and/or a composition comprising said polypeptide, said polynucleotide, said vector, or said host cell, a substrate of said polypeptide, and an acceptor comprising at least one hydroxyl moiety; and ii) incubating said mixture obtained in step i) so as to obtain the connection of glucosyl units in alpha-1,3 on said acceptor.
 18. A composition comprising an acceptor connected to glucosyl units in alpha-1,3 as defined in claim 16 as a thickener, emulsifier and/or stabiliser, wherein said composition is a formulation selected from the group consisting of food industrial, cosmetic, agrochemical, petrochemical and pharmaceutical formulations.
 19. A method of providing a prebiotic effect comprising administering to a subject in need there of an effective amount of an acceptor connected to glucosyl units in alpha-1,3 as defined in claim 16 as an agent with prebiotic effect. 